The dispute involves new guidelines from the American Academy of Pediatrics, which say medical evidence shows the drug benefits few children other than very young preemies. Company spokeswoman Alisha Martin said it placed full-page ads in The New York Times and several other newspapers because "we felt it important to inform parents — including the half-a-million women who give birth prematurely each year — of the decisions being made that could impact the lives of their children." Studies show the drug can slightly reduce risks for being hospitalized but doesn't shorten hospital stays or lessen chances for long-term complications or death, said Dr.